2023-05-11-弘则研究-医疗健康行业2023H2_国内诊疗和融资恢复_品质产品国际化元年_146页_10mb

Analysis Summary of China's Healthcare Industry (2023 H2)

China's healthcare sector in H2 2023 demonstrates a clear bifurcation: high-value manufacturers see significant opportunities in international expansion, while traditional players face headwinds from cost controls. Key themes include DRG payment reform (deepening nationwide implementation), high-value medical procurement (spinal implants, orthopedic materials), and biological drug innovation, where fewer firms are capturing market share.

Internationalization accelerates— domestic firms now compete with global standards, improving technical capabilities and channel reach. Contrarian insights emphasize that pricing power is shifting toward domestic players, and valuation for high-growth segments like mRNA vaccines has stabilized.

英文翻译为中文总结 (Summary of China's Healthcare Industry (2023 H2))

2023年上半年，中国医疗行业显现出明显的上下分化趋势：高价值制造商在国际化布局中获得显著增长，而传统企业则面临集采、控费等多重压力。核心趋势包括：

1. 医保支付改革深化：DRG/DIP付费模式全国推广，叠加带量采购政策常态化，医院端利润空间被压缩，医疗设备、耗材企业受益于“进口替代+国产产品性能提升”的双重逻辑。

2. 高值耗材竞争格局重塑：脊柱、关节、电生理等细分领域集采加速，头部企业通过产品力优势维持份额，中小型企业面临渠道重构风险。种植牙及角膜塑形镜等新兴品类集采方案落地，倒逼产品创新。

3. 创新药进入2.0时代："me-too"药物占比下降，差异化创新（如CGT、mRNA疫苗原材料国产化）成为价值主线。2023年科创板生物药获批数量同比增长70%，研发费用率持续上行。

4. 消费医疗需求结构分化：眼科-口腔类赛道在集采利基下估值修复，医疗美容渗透率提升，但精准获客能力决定成长天花板。

Disclaimer

This report is issued by 弘则弥道（上海）投资咨询有限公司 on internal use basis only. All data and analysis derive from public sources and market research; we do not constitute formal investment advice. Unsecured transmission or distribution is expressly prohibited.